72963907
liked and commented on
Columns First-Mover Advantage: Novo Nordisk and Eli Lilly Have at Least Four-Year Monopoly Periods Ahead
1.The success of Wegovy is just the beginning for GLP-1 medications.
Since its approval in June 2021, the obesity treatment market has undergone a significant transformation. Wegovy, as a GLP-1 medication, has achieved tremendous success. Its effectiveness surpasses that of previously marketed weight-loss drugs, and it is also considered safer.
According to Barclays' predictions, there is still enorm...
Since its approval in June 2021, the obesity treatment market has undergone a significant transformation. Wegovy, as a GLP-1 medication, has achieved tremendous success. Its effectiveness surpasses that of previously marketed weight-loss drugs, and it is also considered safer.
According to Barclays' predictions, there is still enorm...
![First-Mover Advantage: Novo Nordisk and Eli Lilly Have at Least Four-Year Monopoly Periods Ahead](https://ussnsimg.moomoo.com/73219530/editor_image/910028fd6463384881865ef79e6d7c86.png/thumb)
![First-Mover Advantage: Novo Nordisk and Eli Lilly Have at Least Four-Year Monopoly Periods Ahead](https://ussnsimg.moomoo.com/73219530/editor_image/3625066a70f231e2adfd0e5290c85d3b.png/thumb)
![First-Mover Advantage: Novo Nordisk and Eli Lilly Have at Least Four-Year Monopoly Periods Ahead](https://ussnsimg.moomoo.com/73219530/editor_image/6b56dce1cad43e508d30aec0c9623e97.png/thumb)
+6
12
7
72963907 70598432 : Ask your friends to follow him. Win his attention.